Chemotherapy in the Elderly

Seminars in Oncology

Volumn 31, Issue 2, 2004, Pages 160-174

  Lichtman, Stuart M ^a  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ALLOPURINOL; BLEOMYCIN; CARBOPLATIN; CARMUSTINE; CELECOXIB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; FLUDARABINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; HYDROXYUREA; IDARUBICIN; IFOSFAMIDE; INTERFERON; IRINOTECAN; MELPHALAN; METHOTREXATE; MITOXANTRONE; NEOMYCIN; THALIDOMIDE; THYMIDINE; TOPOTECAN; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG ABSORPTION; DRUG METABOLISM; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; KIDNEY FAILURE; LEUKOPENIA; LIVER FAILURE; MALE; META ANALYSIS; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PATIENT COMPLIANCE; PHARMACODYNAMICS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; THROMBOCYTOPENIA; UNITED STATES; VOMITING;

EID: 1842631407     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2003.12.027     Document Type: Article

References (179)

1. Murray CJ, Lopez AD: Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 349:1498-1504, 1997
2. Franceschi S, La Vecchia C: Cancer epidemiology in the elderly. Crit Rev Oncol Hematol 39:219-226, 2001
3. Balducci L, Extermann M: Cancer and aging. An evolving panorama. Hematol Oncol Clin North Am 14:1-16, 2000
4. Yancik R, Ries LA: Aging and cancer in America. Demographic and epidemiologic perspectives. Hematol Oncol Clin North Am 14:17-23, 2000
5. Hamerman D: Toward an understanding of frailty. Ann Intern Med 130:945-950, 1999
6. Morris LA, Grossman R, Barkdoll G, et al: Information search activities among elderly prescription drug users. J Health Care Mark 7:5-15, 1987
7. Schmucker DL: Drug disposition in the elderly: a review of the critical factors. J Am Geriatr Soc 32:144-149, 1984
8. Yuen GJ: Altered pharmacokinetics in the elderly. Clin Geriatr Med 6:257-267, 1990
9. Baker SD, Grochow LB: Pharmacology of cancer chemotherapy in the older person. Clin Geriatr Med 13:169-183, 1997
10. Kastrissios H, Blaschke TF: Medication compliance as a feature in drug development. Annu Rev Pharmacol Toxicol 37:451-475, 1997
11. Egorin MJ: Cancer pharmacology in the elderly. Semin Oncol 20:43-49, 1993
12. Rossman I: Clinical Geriatrics. (ed 2). Philadelphia, PA, Lippincott, 1979
13. Eisenhauer EA, Vermorken JB, van Glabbeke M: Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: A multivariate analysis of 704 patients. Ann Oncol 8:963-968, 1997
14. Teicher BA, Ara G, Herbst R, et al: PEG-hemoglobin: effects on tumor oxygenation and response to chemotherapy. In Vivo 11:301-311, 1997
15. Schrijvers D, Highley M, De Bruyn E, et al: Role of red blood cells in pharmacokinetics of chemotherapeutic agents. Anticancer Drugs 10:147-153, 1999
16. Rieseman C: Antidepressant drug interactions and the cytochrome P450 system: A critical appraisal. Pharmacotherapy 15:84S-99S, 1995
17. Michalets EL: Update: Clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 18:84-112, 1998
18. Evans W, Schentag J, Jusko W: Applied Pharmacokinetics, Principles of Therapeutic Drug Monitoring (ed 3). Vancouver, WA, Applied Therapeutics, Inc, 1994
19. Flockhart D: Cytochrome P450 drug interaction table. Available at: http://medicine.iupui.edu/flockhart/. Accessed Sept 18, 2002
20. Sotaniemi EA, Arranto AJ, Pelkonen O, et al: Age and cytochrome P450-linked drug metabolism in humans: An analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther 61:331-339, 1997
21. Vestal RE: Aging and pharmacology. Cancer 80:1302-1310, 1997
22. Balducci L, Corcoran MB: Antineoplastic chemotherapy of the older cancer patient. Hematol Oncol Clin North Am 14:193-212, 2000
23. Brenner BM, Meyer GW, Hostetter TH: Dietary protein intake and the progressive nature of kidney disease: The role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 307:652-659, 1982
24. Tauchi H, Tsuboi K, Okutoni J: Age changes in the human kidney of the different races. Gerontology 17:87-97, 1971
25. Evers BM, Townsend CMJ, Thompson JC: Organ physiology of aging. Surg Clin North Am 74:23-39, 1994
26. Gelman RS, Taylor SGT: Cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: The elimination of age trends in toxicity by using doses based on creatinine clearance. J Clin Oncol 2:1404-1413, 1984
27. Swedko PJ, Clark HD, Paramsothy K, et al: Serum creatinine is an inadequate screening test for renal failure in elderly patients. Arch Intern Med 163:356-360, 2003
28. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41, 1976
29. Jelliffe RW: Estimation of creatinine clearance when urine cannot be collected. Lancet 1:975-976, 1971
30. Smythe M, Hoffman J, Kizy K, et al: Estimating creatinine clearance in elderly patients with low serum creatinine concentrations. Am J Hosp Pharm 51:198-204, 1994
31. Marx GM, Steer CB, GaIani E, et al: Evaluation of the Cockroft Gault, Jelliffe and Wright formulae in estimating renal function in elderly patients. Proc Am Soc Clin Oncol 21:1486a, 2002 (abstr)
32. Burkhardt H, Bojarsky G, Gretz N, et al: Creatinine clearance, Cockcroft-Gault formula and cystatin C: Estimators of true glomerular filtration rate in the elderly? Gerontology 48:140-146, 2002
33. Balducci L, Extermann M: Cancer chemotherapy in the older patient: What the medical oncologist needs to know. Cancer 80:1317-1322, 1997
34. Skirvin JA, Lichtman SM: Pharmacokinetic considerations of oral chemotherapy in elderly patients with cancer. Drugs Aging 19:25-42, 2002
35. Calvert AH, Newell DR, Gumbrell LA, et al: Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748-1756, 1989
36. Chatelut E, Canal P, Brunner V, et al: Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 87:573-580, 1995
37. Kintzel PE, Dorr RT: Anticancer drug renal toxicity and elimination: Dosing guidelines for altered renal function. Cancer Treat Rev 21:33-64, 1995
38. Charlson ME, Pompei P, Ales KL, et al: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373-383, 1987
39. Satariano WA, Ragland DA: The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 120:104-110, 1994
40. Yancik R, Wesley MN, Ries LA, et al: Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: A population-based study. Cancer 82:2123-2134, 1998
41. Extermann M, Overcash J, Lyman GH, et al: Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 16:1582-1587, 1998
42. Rockwood K, Stadnyk K, MacKnight C, et al: A brief clinical instrument to classify frailty in elderly people. Lancet 353:205-206, 1999
43. Reuben DB, Rubenstein LV, Hirsch SH, et al: Value of functional status as a predictor of mortality: Results of a prospective study. Am J Med 93:663-669, 1992
44. Repetto L, Vercelli M, Simoni C, et al: Comorbidity among elderly patients with and without cancer. Proc Am Soc Clin Oncol 13:1625a, 1994 (abstr)
45. Venook AP, Egorin MJ, Rosner GL, et al: Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol 18:2780-2787, 2000
46. Shepherd FA, Abratt RP, Anderson H, et al: Gemcitabine in the treatment of elderly patients with advanced non-small cell lung cancer. Semin Oncol 24:S50-S55, 1997 (suppl 7)
47. Crivellari D, Bonetti M, Castiglione-Gertsch M, et al: Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: The International Breast Cancer Study Group Trial VII. J Clin Oncol 18:1412-1422, 2000
48. Iyer L, Ratain MJ: 5-Fluorouracil pharmacokinetics: Causes for variability and strategies for modulation in cancer chemotherapy. Cancer Invest 17:494-506, 1999
49. Diasio RB: Clinical implications of dihydropyrimidine dehydrogenase inhibition. Oncology (Huntingt) 13:17-21, 1999
50. Diasio RB: The role of dihydropyrimidine dehydrogenase (DPD) modulation in 5-FU pharmacology. Oncology (Huntingt) 12:23-27, 1998
51. Grem JL: 5-Fluoropyrimidines: Cancer Chemotherapy and BiotherapyPrinciples and Practicein Chabner BA, Longo DL. ed 2. Philadelphia, PA, Lippincott-Raven, 1996, pp 149-211
52. Sloan JA, Goldberg RM, Sargent DJ, et al: Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol 20:1491-1498, 2002
53. Macdonald JS: Vive la difference: Sex and fluorouracil toxicity. J Clin Oncol 20:1439-1441, 2002
54. Stein BN, Petrelli NJ, Douglass HO, et al: Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer 75:11-17, 1995
55. Popescu RA, Norman A, Ross PJ, et al: Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 17:2412-2418, 1999
56. Chiara S, Nobile M, Vincenti M, et al: Advanced colorectal cancer in the elderly: Results of consecutive trials with 5-fluorouracil-based chemotherapy. Cancer Chemother Pharmacol 42:336-340, 1998
57. Sargent DJ, Goldberg RM, Jacobson SD, et al: A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345:1091-1097, 2001
58. Adkins JC, Peters DH, Markham A: Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies. Drugs 53:1005-1037, 1997
59. Lichtman SM, Etcubanas E, Budman DR, et al: The pharmacokinetics and pharmacodynamics of fludarabine phosphate in patients with renal impairment: A prospective dose adjustment study. Cancer Invest 20:904-913, 2002
60. Beran M, Kantarjian H, O'Brien S, et al: Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 88:2473-2479, 1996
61. Relias V, Skirvin JA: Topoisomerase I inhibitors: 1. Topotecan. J Oncol Pharm Pract 3:173-185, 1997
62. O'Reilly S, Armstrong DK, Grochow LB: Life-threatening myelosuppression in patients with occult renal impairment receiving topotecan. Gynecol Oncol 67:329-330, 1997 (letter)
63. von Pawel J, Gatzemeier U, Pujol J, et al: Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol 19:1743-1749, 2001
64. Tardi P, Choice E, Masin D, et al: Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models. Cancer Res 60:3389-4493, 2000
65. Clarke-Pearson D, Van LL, Iveson T, et al: Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer. J Clin Oncol 19:3967-3975, 2001
66. Friedman HS, Petros WP, Friedman AH, et al: Irinotecan therapy in adults with recurrent of or progressive malignant glioma. J Clin Oncol 17:1516-1525, 1999
67. Saltz LB, Douillard J-Y, Pirotta N, et al: Combined analysis of two phase 3 randomized trials comparing irinotecan (C), fluorouracil (F), leucovorin (L) vs F alone as first-line therapy of previously untreated metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 19:938a, 2000 (abstr)
68. Saltz LB: Irinotecan in the first-line treatment of colorectal cancer. Oncology (Huntingt) 12:54-58, 1998
69. Rougier P, Van Cutsem E, Bajetta E, et al: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer [published erratum appears in Lancet 352:1634, 1998]. Lancet 352:1407-1412, 1998
70. Rougier P, Van Cutsem E, Bajetta E, et al: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer [published erratum appears in Lancet 352:1634, 1998]. Lancet 352:1407-1412, 1998
71. Fuchs CS, Moore MR, Harker G, et al: Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 21:807-814, 2003
72. Mick R, Gupta E, Vokes EE, et al: Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: Prediction of biliary index and intestinal toxicity. J Clin Oncol 14:2012-2019, 1996
73. Skirvin J, Relias V: Topoisomerase inhibitors: 2. Irinotecan. J Oncol Pharm Pract 4:103-116, 1998
74. Rothenberg ML, Cox JV, DeVore RF, et al: A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer 85:786-795, 1999
75. Kehrer DF, Sparreboom A, Verweij J, et al: Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients. Clin Cancer Res 7:1136-1141, 2001
76. Govindarajan R, Heaton KM, Broadwater R, et al: Effect of thalidomide on gastrointestinal toxic effects of irinotecan. Lancet 356:566-567, 2000
77. Lin EH, Morris J, Chau NK, et al: Celecoxib attenuated capecitabine induced hand-and-foot syndrome (HFS) and diarrhea and improved time to tumor progression in metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 21:2362, 2002 (abstr)
78. Singal PK, Iliskovic N: Doxorubicin-induced cardiomyopathy. N Engl J Med 339:900-905, 1998
79. Swain SM, Whaley FS, Gerber MC, et al: Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 15:1318-1332, 1997
80. Doroshow JH: Anthracyclines and anthracenediones, in Chabner BA, Longo DL (eds): Cancer Chemotherapy and Biotherapy: Principles and Practice (ed 2). Philadelphia, PA, Lippincott-Raven, 1996, pp 409-434
81. Doroshow JH: Doxorubicin-induced cardiac toxicity. N Engl J Med 324:843-845, 1991
82. McEvoy GK: AHFS 98: Drug Information. Bethesda, MD, American Society of Health System Pharmacists, 1998
83. Dorr RT, Von Hoff DD: Cancer Chemotherapy Handbook (ed 2). Norwalk, CT, Appleton & Lange, 1994
84. Ibrahim NK, Hortobagyi GN, Ewer M, et al: Doxorubicin-induced congestive heart failure in elderly patients with metastatic breast cancer, with long-term follow-up: The M.D. Anderson experience. Cancer Chemother Pharmacol 43:471-478, 1999
85. Ibrahim NK, Frye DK, Buzdar AU, et al: Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer. Tolerance and outcome. Arch Intern Med 156:882-888, 1996
86. Ibrahim NK, Buzdar AU, Asmar L, et al: Doxorubicin-based adjuvant chemotherapy in elderly breast cancer patients: The M.D. Anderson experience, with long-term follow-up. Ann Oncol 11:1597-1601, 2000
87. Dees EC, O'Reilly S, Goodman SN, et al: A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer. Cancer Invest 18:521-529, 2000
88. Platel D, Pouna P, Bonoron-Adele S, et al: Comparative cardiotoxicity of idarubicin and doxorubicin using the isolated perfused rat heart model. Anticancer Drugs 10:671-676, 1999
89. Robieux I, Spazzapan S, Fratino L, et al: Pharmacokinetics and safety of idarubicin containing infusion (CIV) in elderly patients with aggressive lymphoma. Proc Am Soc Clin Oncol 17:854a, 1998 (abstr)
90. Anderlini P, Benjamin RS, Wong FC, et al: Idarubicin cardiotoxicity: A retrospective study in acute myeloid leukemia and myelodysplasia. J Clin Oncol 13:2827-2834, 1995
91. Spielmann M, Tubiana-Hulin M, Namer M, et al: Sequential or alternating administration of docetaxel (Taxotere) combined with FEC in metastatic breast cancer: A randomised phase II trial. Br J Cancer 86:692-697, 2002
92. Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: An Italian multicentre trial. Italian Multicentre Breast Study with Epirubicin. J Clin Oncol 6:976-982, 1988
93. Praga C, Trave F, Petroccione A, et al: Anthracycline-induced cardiotoxicity and its relevance in cancer treatment, in Nimmo W, Tucker G (eds): Clinical Measurement in Drug Evaluation. London, UK, Wolfe Publishing, 1991, pp 131-142
94. Nicolella D, Grimaldi G, Colantuoni G, et al: Weekly low dose epirubicin in elderly cancer patients. Tumori 82:369-371, 1996
95. 2. Ann Oncol 11:1029-1033, 2000
96. Muggia FM: Clinical efficacy and prospects for use of pegylated liposomal doxorubicin in the treatment of ovarian and breast cancers. Drugs 54:22-29, 1997 (suppl 4)
97. Thomas X, Archimbaud E: Mitoxantrone in the treatment of acute myelogenous leukemia: a review. Hematol Cell Ther 39:63-74, 1997
98. Ranson MR, Carmichael J, O'Byrne K, et al: Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol 15:3185-3191, 1997
99. Lichtman SM, Kolitz J, Budman DR, et al: Treatment of aggressive non-Hodgkin's lymphoma in elderly patients with thiotepa, novantrone (mitoxantrone), vincristine, prednisone (TNOP). Am J Clin Oncol 24:360-362, 2001
100. Wiseman LR, Spencer CM: Mitoxantrone. A review of its pharmacology and clinical efficacy in the management of hormone-resistant advanced prostate cancer. Drugs Aging 10: 473-485, 1997
101. Small EJ: Prostate cancer. Curr Opin Oncol 9:277-286, 1997
102. Cortes JE, Pazdur R: Docetaxel. J Clin Oncol 13:2643-2655, 1995
103. Kreis W, Budman DR, Fetten J, et al: Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann Oncol 10:33-38, 1999
104. Venook AP, Egorin MJ, Rosner GL, et al: Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. J Clin Oncol 16:1811-1819, 1998
105. Taylor CW, Wang LM, List AF, et al: Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained. Eur J Cancer 33:1693-1698, 1997
106. Hainsworth JD, Burris HA III, Erland JB, et al: Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 16:2164-2168, 1998
107. Hainsworth JD, Burris HA III, Litchy S, et al: Weekly docetaxel in the treatment of elderly patients with advanced non-small cell lung carcinoma. A Minnie Pearl Cancer Research Network phase II trial. Cancer 89:328-333, 2000
108. Perez EA, Vogel CL, Irwin DH, et al: Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 19:4216-4223, 2001
109. Perez EA, Vogel CL, Irwin DH, et al: Weekly paclitaxel in women age 65 and above with metastatic breast cancer. Breast Cancer Res Treat 73:85-88, 2002
110. Lichtman SM, Egorin M, Rosner G, et al: Clinical pharmacology of paclitaxel in relation to patient age: CALGB 9762. Proc Am Soc Clin Oncol 19:265a, 2001 (abstr)
111. Akerley W, Glantz M, Choy H, et al: Phase I trial of weekly paclitaxel in advanced lung cancer. J Clin Oncol 16: 153-158, 1998
112. Vahdat L, Papadopoulos K, Lange D, et al: Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Clin Cancer Res 7:1192-1197, 2001
113. Burris H: Optimal use of docetaxel (Taxotere): Maximizing its potential. Anticancer Drugs 7:25-28, 1996 (suppl 2)
114. Bruno R, Hille D, Riva A, et al: Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 16:187-196, 1998
115. Reed E, Dabholkar M, Chabner BA: Platinum analogues, in Chabner BA, Longo DL (eds): Cancer Chemotherapy and Biotherapy: Principles and Practice (ed 2). Philadelphia, PA, Lippincott-Raven, 1996, pp 357-378
116. Hesketh PJ: Treatment of chemotherapy-induced emesis in the 1990s: Impact of the 5-HT3 receptor antagonists. Support Care Cancer 2:286-292, 1994
117. Lofters W, Pater J, Zee B, et al: Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. J Clin Oncol 15:2966-2973, 1997
118. Blanchley JD, Hill JB: Renal and electrolyte disturbances associated with Cisplatin. Ann Intern Med 95:628-632, 1981
119. Daugaard G, Abildgaard U: Cisplatin nephrotoxicity. Cancer Chemother Pharmacol 25:1-9, 1988
120. Becouarn Y, Nguyen B, Brunet R, et al: Cancer chemotherapy in the elderly: A series of 51 patients aged >70 years. Cancer Chemother Pharmacol 29:159-163, 1992
121. Hrushesky WJM, Shimp W, Kennedy BJ: Lack of age-dependent cisplatin nephrotoxicity. Am J Med 76:579-584, 1984
122. Thyss A, Saudes L, Otto J, et al: Renal tolerance of cisplatin in patients more than 80 years old. J Clin Oncol 12:2121-2125, 1994
123. Lichtman SM, Buchholtz M, Marino J, et al: Use of cisplatin for elderly patients. Age Ageing 21:202-204, 1992
124. Cubillo A, Cornide M, Lopez JL, et al: Renal tolerance to cisplatin in patients 70 years and older. Am J Clin Oncol 24:192-197, 2001
125. Langer CJ, Manola J, Bernardo P, et al: Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: Implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 94:173-181, 2002
126. Lichtman SM: Physiologic aspects of aging. Implications for the treatment of cancer. Drugs Aging 7:212-225, 1995
127. Kemp G, Rose P, Lurain J, et al: Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: Results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 14:2101-2112, 1996
128. Dooley MJ, Poole SG, Rischin D, et al: Carboplatin dosing: gender bias and inaccurate estimates of glomerular filtration rate. Eur J Cancer 38:44-51, 2002
129. Donahue A, McCune JS, Faucette S, et al: Measured versus estimated glomerular filtration rate in the Calvert equation: Influence on carboplatin dosing. Cancer Chemother Pharmacol 47:373-379, 2001
130. Calvert AH, Egorin MJ: Carboplatin dosing formulae: gender bias and the use of creatinine-based methodologies. Eur J Cancer 38:11-16, 2002
131. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947, 2000
132. Tabah-Fisch I, Maindrault-Goebel F, Benavides M, et al: Oxaliplatin/5FU/LV is feasible, safe and active in elderly colorectal cancer (CRC) patients. Proc Am Soc Clin Oncol 21:556a, 2002 (abstr)
133. Miller AA, Rosner GL, Ratain MJ, et al: Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: A Cancer and Leukemia Group B study (CALGB 9062). Clin Cancer Res 3:719-725, 1997
134. de Jong RS, Hofstra LS, Willemse PH, et al: Effect of low-dose oral etoposide on serum CA-125 in patients with advanced epithelial ovarian cancer. Gynecol Oncol 66:197-201, 1997
135. Fleming GF, Waggoner SE, Rotmensch J, et al: Phase II study of 96-hr continuous-infusion etoposide and doxorubicin with bolus cyclophosphamide in refractory epithelial ovarian cancer. Gynecol Oncol 65:42-45, 1997
136. Niitsu N, Umeda M: Evaluation of long-term daily administration of oral low-dose etoposide in elderly patients with relapsing or refractory non-Hodgkin's lymphoma. Am J Clin Oncol 20:311-314, 1997
137. Gridelli C, Rossi A, Scognamiglio F, et al: Carboplatin plus oral etoposide in elderly patients with advanced non small cell lung cancer. A phase II study. Anticancer Res 17:4755-4758, 1997
138. Souhami RL, Spiro SG, Rudd RM, et al: Five-day oral etoposide treatment for advanced small-cell lung cancer: Randomized comparison with intravenous chemotherapy. J Natl Cancer Inst 89:577-580, 1997
139. McEvoy G: AHFS 2000. Drug Information. Bethesda, MD, American Society of Health System Pharmacists, 2000
140. Aita P, Robieux I, Sorio R, et al: Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma. Cancer Chemother Pharmacol 43:287-294, 1999
141. LeChevalier T, Brisgand D, Douilland J-Y, et al: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients. J Clin Oncol 12:360-367, 1994
142. Burger RA, DiSaia PJ, Roberts JA, et al: Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer. Gynecol Oncol 72:148-153, 1999
143. Budman DR: Vinorelbine (Navelbine): A third-generation vinca alkaloid. Cancer Invest 15:475-490, 1997
144. Frasci G, Lorusso V, Panza N, et al: Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 18:2529-2536, 2000
145. Sorio R, Robieux I, Galligioni E, et al: Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer. Eur J Cancer 33:301-303, 1997
146. Gauvin A, Pinguet F, Culine S, et al: Bayesian estimate of vinorelbine pharmacokinetic parameters in elderly patients with advanced metastatic cancer. Clin Cancer Res 6:2690-2695, 2000
147. Greco FA: Evolving role of oral chemotherapy for the treatment of patients with neoplasms. Oncology 12:43-50, 1998
148. Liu G, Franssen E, Fitch MI, et al: Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15:110-115, 1997
149. DeMario MD, Ratain MJ: Oral chemotherapy: rationale and future directions. J Clin Oncol 16:2557-2567, 1998
150. Bonadonna G, Valagussa P: Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304: 101-105, 1981
151. Lebovits AH, Strain JJ, Schleifer SJ, et al: Patient noncompliance with self-administered chemotherapy. Cancer 65:17-22, 1990
152. Partridge AH, Avorn J, Wang PS, et al: Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 94:652-661, 2002
153. Cramer JA: Enhancing patient compliance in the elderly. Role of packaging aids and monitoring. Drugs Aging 12:7-15, 1998
154. Corcoran ME: Polypharmacy in the older patient with cancer. Cancer Control 4:419-428, 1997
155. Kivisto KT, Kroemer HK, Eichelbaum M: The role of human cytochrome P450 enzymes in the metabolism of anti-cancer agents: Implications for drug interactions. Br J Clin Pharmacol 40:523-530, 1995
156. King RS: Drug interactions with cancer chemotherapy. Cancer Pract 3:57-59, 1995
157. Cloutier AO: Advanced breast cancer: recent developments in hormonal therapy. Semin Oncol Nurs 16:206-213, 2000
158. Crucitta E, Lorusso V, Attolico M, et al: New aromatase inhibitors in the treatment of advanced breast cancer. Int J Oncol 17:1037-1041, 2000
159. Van Cutsem E, Findlay M, Osterwalder B, et al: Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: Results of a randomized phase II study. J Clin Oncol 18:1337-1345, 2000
160. O'Shaughnessy J, Moiseyenko V, Bell DV, et al: A randomized phase II study of Xeloda (capecitabine) vs CMF as first line chemotherapy of breast cancer in women aged 55 years. Proc Am Soc Clin Oncol 17:398a, 1998
161. Cassidy J, Twelves C, Cameron D, et al: Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients. Cancer Chemother Pharmacol 44:453-460, 1999
162. Twelves C, Glynne-Jones R, Cassidy J, et al: Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Clin Cancer Res 5:1696-1702, 1999
163. O'Shaughnessy JA: Potential of capecitabine as first-line therapy for metastatic breast cancer: Dosing recommendations in patients with diminished renal function. Ann Oncol 13:983, 2002 (letter)
164. Reigner B, Verweij J, Dirix L, et al: Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. Clin Cancer Res 4:941-948, 1998
165. Middleton MR, Grob JJ, Aaronson N, et al: Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18:158-166, 2000
166. Newlands ES, O'Reilly SM, Glaser MG, et al: The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur J Cancer 32A:2236-2241, 1996
167. O'Reilly SM, Newlands ES, Glaser MG, et al: Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur J Cancer 29A:940-942, 1993
168. Yung WK, Prados MD, Yaya-Tur R, et al: Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 17:2762-2771, 1999
169. Jen JF, Cutler DL, Pai SM, et al: Population pharmacokinetics of temozolomide in cancer patients. Pharm Res 17:1284-1289, 2000
170. Brada M, Judson I, Beale P, et al: Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br J Cancer 81:1022-1030, 1999
171. D'Amato RJ, Loughnan MS, Flynn E, et al: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 91:4082-4085, 1994
172. Burton E, Prados M: New chemotherapy options for the treatment of malignant gliomas. Curr Opin Oncol 11:157-161, 1999
173. Singhal S, Mehta J, Desikan R, et al: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565-1571, 1999
174. Fine HA, Figg WD, Jaeckle K, et al: Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 18:708-715, 2000
175. Chabner BA, Longo DL: Cancer Chemotherapy and Biotherapy. Principles and Practice. Philadelphia, PA, Lippincott-Raven, 1996
176. Rodriguez GI, Kuhn JG, Weiss GR, et al: A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea. Blood 91:1533-1541, 1998
177. Tew KD, Colvin M, Chabner BA: Alkylating agents, in Chabner BA, Longo DL (eds): Cancer Chemotherapy and Biotherapy: Principles and Practice (ed 2). Philadelphia, PA, Lippincott-Raven, 1996, pp 297-332
178. Trimble EL, Carter CL, Cain D, et al: Representation of older patients in cancer treatment trials. Cancer 74:2208-2214, 1994
179. Lichtman SM: Integration of geriatrics in oncology training-The relationship between the academic center and the community. Crit Rev Oncol Hematol 33:57-59, 2000